Verrica Pharmaceuticals Inc. VRCA
4.37
0.01
0.23%
as of 25 Sep
- Market cap
- $74.9M
- P/E
- 0.0×
Follow VRCA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
2.49 | 4.79 | 60.26 | 10.89 | 0.00 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
(19.28) | (2.26) | (21.28) | (19.86) | (28.48) | — | — | — | — | — |
P/B ratio |
3.58 | 0.00 | 15.62 | 2.46 | 7.60 | — | — | — | — | — |
Price to Tangible BV |
3.58 | 0.00 | 15.62 | 2.46 | 7.60 | — | — | — | — | — |
EV/Sales |
2.01 | 4.58 | 55.32 | 7.27 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(4.05) | (0.57) | (7.35) | (3.52) | (7.94) | — | — | — | — | — |
EV/FCF |
(4.00) | (0.57) | (7.28) | (3.43) | (7.64) | — | — | — | — | — |
Quick Ratio |
2.16 | 1.60 | 4.34 | 10.05 | 1.53 | 1.66 | 18.51 | 36.26 | 14.06 | 1.26 |
Current Ratio |
2.59 | 1.76 | 4.55 | 11.31 | 1.61 | 1.71 | 19.39 | 36.80 | 14.75 | 1.30 |
Net Debt/EBITDA |
2.59 | 0.03 | 0.40 | 1.60 | 0.94 | 0.71 | 2.07 | 4.11 | 1.94 | 0.28 |
Debt/Assets |
1.36% | 82.55% | 53.80% | 3.41% | 52.05% | 49.91% | 0.27% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.03 | (4.53) | 2.22 | 0.04 | 1.28 | 1.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.70 | 0.11 | 0.08 | 0.14 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.99 | 0.80 | 0.58 | 0.76 | 0.79 | 0.71 | 0.97 | 0.87 | 0.47 | 0.84 |
Capex/Depreciation |
0.00 | (0.01) | (0.43) | (0.58) | (2.01) | (7.38) | (7.42) | (38.70) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (240.35%) | (1,546.58%) | (224.08%) | (67.42%) | (106.97%) | (87.13%) | (36.53%) | (50.12%) | 201.11% | 39.42% | |
| (35.33%) | (112.84%) | (106.07%) | (39.23%) | (45.48%) | (59.89%) | (35.19%) | (40.89%) | (202.74%) | (39.74%) | |
ROIC |
0.00% | 0.00% | 0.00% | (182.68%) | (487.82%) | (555.11%) | (590.08%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(67.98%) | (336.52%) | (108.83%) | (61.92%) | (109.06%) | (136.50%) | (44.27%) | (23.22%) | (115.26%) | (1,530.40%) |
Average Days of Receivables |
55.37 | 3.71 | 314.57 | 19.68 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
24.89% | 156.49% | 396.08% | 135.05% | 132.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
99.00% | 777.45% | 923.20% | 192.70% | 224.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.33% | 94.69% | 280.56% | 55.19% | 50.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.23 | (0.35) | 0.05 | 0.35 | 0.11 | — | — | — | — | — |
Graham Number |
0.00 | 25.68 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(19.01%) | (220.00%) | (21.44%) | (28.40%) | (14.08%) | — | — | — | — | — |
Free Cash Flow Yield |
(20.19%) | (168.68%) | (12.61%) | (19.45%) | (11.57%) | — | — | — | — | — |
Revenue per Share |
3.34 | 1.46 | 1.13 | 2.64 | 4.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.65) | (11.76) | (8.51) | (5.46) | (10.20) | (12.08) | (11.01) | (12.19) | (16.08) | (4.37) |
Capex per Share |
0.00 | 0.00 | (0.08) | (0.14) | (0.40) | (0.68) | (0.77) | (0.53) | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.65) | (11.76) | (8.59) | (5.60) | (10.60) | (12.76) | (11.77) | (12.72) | (16.08) | (4.37) |
Cash per Share |
2.83 | 8.94 | 15.34 | 10.03 | 26.01 | 26.19 | 24.91 | 61.25 | 30.40 | 1.43 |
Shareholders Equity per Share |
2.32 | (1.90) | 4.36 | 11.72 | 12.06 | 13.20 | 26.11 | 60.99 | 29.71 | 0.34 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.32 | (1.90) | 4.36 | 11.72 | 12.06 | 13.20 | 26.11 | 60.99 | 29.71 | 0.34 |
Free Cash Flow |
(17.63) | (60.95) | (38.94) | (19.13) | (28.67) | (31.90) | (29.31) | (18.65) | (4.58) | (1.61) |
Working Capital |
26.10 | 22.17 | 60.51 | 35.66 | 28.27 | 28.18 | 61.63 | 88.68 | 8.47 | 0.13 |
Capital Expenditures |
— | (0.02) | (0.36) | (0.48) | (1.08) | (1.69) | (1.91) | (0.77) | — | — |
Net Current Asset Value |
20.15 | (12.81) | 15.70 | 34.43 | 26.81 | 26.48 | 61.57 | 88.68 | 8.47 | 0.13 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.05 | 0.09 | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
(50.27%) | (1,012.15%) | (1,307.47%) | (271.11%) | (292.33%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.74 | 2.15 | 0.79 | 0.21 | 0.14 | 0.07 | 0.12 | 0.08 | — | — |
Cash ROIC |
(32.12%) | (75.80%) | (29.75%) | (29.72%) | (21.76%) | (24.59%) | (23.19%) | (10.11%) | (26.75%) | (247.09%) |
Accounts Receivable Turnover |
13.00 | 3.37 | 2.09 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
1.73 | 1.26 | 0.50 | 1.07 | 0.79 | 0.30 | 0.24 | 0.04 | 0.00 | 0.00 |
Inventory Turnover |
1.46 | 1.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
219.78 | 252.57 | 1,205.58 | 255.25 | 653.44 | 554.67 | 1,681.67 | 17,261.08 | 0.00 | 0.00 |
Days of Inventory on Hand |
237.18 | 328.10 | 500.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
2.74 | 2.25 | 2.45 | — | — | — | — | — | — | — |
Average Payables |
1.98 | 2.18 | 1.49 | 0.68 | 0.60 | 0.77 | 1.07 | 0.56 | 0.14 | 0.14 |
Average Inventory |
2.35 | 1.74 | — | — | — | — | — | — | — | — |
Average Assets |
50.63 | 67.87 | 63.16 | 62.42 | 77.14 | 71.29 | 80.17 | 50.49 | 4.81 | 4.81 |
Average Common Equity |
7.44 | 4.95 | 29.90 | 36.32 | 32.80 | 49.00 | 77.22 | 41.19 | (4.85) | (4.85) |
Columns are period end dates